What Helix3 does

Helix3, Inc. is a private GLP contract research laboratory headquartered in the Research Triangle area of Morrisville, North Carolina, founded in 1994 with 11–50 employees. The firm specializes in genetic toxicology testing under Good Laboratory Practice standards, with its core offering being the in vivo comet assay conducted on any tissue (liver, kidney, spleen, lung, blood, brain, stomach, and ~18 additional tissue types) across any species or strain for clients requiring regulatory submissions. Supporting services include combined in vivo comet and micronucleus assays, DNA reactivity screening via an in-house acellular comet assay, target organ toxicity tests, investigative and weight-of-evidence studies, study review and evaluation, and experimental design and troubleshooting. Helix3 also operates a Mobile Comet Assay unit that travels within the US and Europe to perform onsite GLP comet sample processing and analysis at client-specified facilities.

The company's scientific foundation is anchored by Marie Z. Vasquez, a recognized Comet Expert who leads the HESI/GTTC Comet Project and was an invited member of the IWGT expert panel that shaped OECD guidelines for the in vivo comet assay. Helix3 positions itself as a niche specialist—combining academic flexibility with GLP quality and reproducibility—rather than a broad CRO. Its regulatory standing was validated in April 2022 when the U.S. FDA Bioresearch Monitoring Program completed an onsite inspection with no findings, and a 2023 IWGT publication identified Helix3 (Lab 2) as having the lowest inter-study variation of all labs evaluated in a comparative historical control data assessment.

Helix3 generates revenue through professional services engagements: customized experimental designs and GLP-compliant studies sold directly to pharmaceutical, chemical, and biotechnology companies whose products must satisfy OECD TG 489, FDA, ECHA, and EFSA requirements for genotoxicity data. Pricing is not publicly disclosed and is quote-based per study. The firm markets primarily through scientific publications, industry conferences (IWGT, HESI/GTTC), and direct enterprise sales rather than traditional demand-generation channels, and it explicitly serves as a single-service specialist (no adjacent service lines documented).

Name

Helix3

Legal name

HELIX3, INC.

Website

https://helix3inc.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

11–50 employees

Short description

Helix3 is a private GLP contract research laboratory in Morrisville, North Carolina, that designs and conducts customized in vivo and in vitro genetic toxicology studies—primarily the comet assay—for pharmaceutical, chemical, and biotechnology companies requiring FDA, ECHA, and EFSA regulatory submissions, augmented by a US/Europe mobile comet unit.

Ownership category

akta.pro rank

Product category

Genetic Toxicology Contract Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

akta.pro secondary industry

Genetic Toxicology (Ames/Micronucleus/Comet) (HLAGAFAE)

Keywords

• Genetic toxicology testing
• Comet assay services
• GLP contract research
• In vivo genotoxicity
• Regulatory toxicology

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. GLP Contract Research Services: Customized in vitro and in vivo laboratory services for research and method development needs. Services are conducted according to GLP quality standards for regulatory submissions in the pharmaceutical, chemical, and biotechnology industries.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Helix3 is a GLP-compliant contract research laboratory that designs and conducts customized in vitro and in vivo genotoxicity laboratory services, specializing in the comet assay and micronucleus assays. The company provides GLP-compliant studies for regulatory submissions to the FDA, ECHA, and EFSA, including DNA reactivity screening, target organ toxicity testing, combined comet/micronucleus assays, mobile onsite comet services, and investigative/weight-of-evidence studies for pharmaceutical, chemical, and biotechnology clients.

Product overview

Helix3 is a GLP (Good Laboratory Practice) contract research laboratory offering a comprehensive portfolio of genotoxicity testing services centered on the comet assay. The core offerings include In Vivo Comet Assay and Combined In Vivo Comet and Micronucleus Assay services conducted under GLP compliance for regulatory submissions across multiple tissue types and species. Supporting services include DNA Reactivity Screening, Target Organ Toxicity Tests, Mobile Comet Assay (onsite services), Method Development, Investigative Studies, Study Review and Evaluation, and Experimental Design and Troubleshooting. The company operates as a single-service provider focused exclusively on comet assay-based genetic toxicology testing since 1994, combining academic-style innovation with GLP quality standards.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vivo Comet Assay GLP-compliant regulated studies conducted in any species or strain on any tissue (including liver, kidney, spleen, lung, brain, colon, and 18 other tissue types) for detecting DNA damage in support of regulatory submissions for pharmaceutical, chemical, and biotechnology clients.
• Combined In Vivo Comet and Micronucleus Assay Integrated testing service combining comet analysis of any tissue with micronucleus evaluation of bone marrow or peripheral blood from the same exposure unit, providing comprehensive genotoxicity assessment.
• DNA Reactivity Screening Screening service using the acellular comet assay to determine direct DNA reactivity of test compounds, including detection of strand breaks, alkali labile sites, and crosslinks, useful for screening early development stage compounds.
• Target Organ Toxicity Tests Screening studies designed to minimize the risk of false positive in vivo genotoxicity test results, evaluating specific target organs for toxic effects.
• Mobile Comet Assay Onsite GLP comet sample processing and analysis conducted at any client-specified facility, clinic, or field site in the US or Europe, addressing situations where client facilities lack comet assay expertise or resources to collect and process fresh comet samples.
• Method Development In vitro, in vivo, and ex vivo methods modified and optimized to accommodate specific exposure, application, or regulatory requirements.
• Investigative Studies Weight-of-evidence (WoE) or mechanistic studies designed and conducted to answer specific questions or support regulatory submissions.
• Study Review and Evaluation Evaluation of previously conducted studies or experiments to determine data validity, identify optimization opportunities, and make recommendations for development progression.
• Experimental Design and Troubleshooting Customized method development, troubleshooting, and validation services to achieve specific research or regulatory objectives.

Quantifiable outcome

• False positive results from other laboratories were overturned by regulatory authorities when Helix3 repeated the studies using standard methods incorporated to minimize procedural bias and variability
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• HESI/GTTC Comet ProjectcoreStrategic or Co-development Partner · 1 September 2021Comet Expert Marie Vasquez is leading the HESI/GTTC Comet Project to make practical recommendations for improving the clarity and applicability of OECD TG 489 across multiple industries. This project includes and encourages input from international regulatory agencies, academia, and industry scientists to ensure important issues like cytotoxicity, data interpretation, and historical control data criteria are adequately addressed.
• BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)coreStrategic or Co-development Partner · 1 July 2016Marie Z. Vasquez (Helix3) and Roland Frötschl (BfArM) co-authored the In Vivo Comet Assay Test Book Chapter in the Genetic Toxicology Testing Laboratory Manual published by Elsevier in June 2016.
• International Workshop on Genotoxicity Testing (IWGT)coreStrategic or Co-development Partner · 1 November 2013Marie Vasquez from Helix3 participated as an invited member of the expert panel. This group was responsible for making the most significant recommendations to the OECD Steering Committee deciding the new OECD guidelines for the in vivo comet assay.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Eurofins Scientific: Global testing services group with genetic toxicology / regulatory safety testing capabilities across multiple geographies — a broad incumbent in the same regulatory testing category.
• Charles River Laboratories: Global full-service preclinical CRO with a large genetic toxicology franchise; offers comet and broader safety packages at scale, often competing with specialty CROs on bundled programs.
• Labcorp Drug Development (Covance): Large CRO offering GLP genetic toxicology within integrated preclinical safety packages; competes with Helix3 for both standalone and bundled genotoxicity awards.
• Inotiv: Preclinical CRO and research models provider offering GLP toxicology and genetic toxicology services — competes in adjacent preclinical testing categories with bundled safety offerings.
• Citoxlab (now part of Charles River): Preclinical CRO with European footprint offering GLP genetic toxicology and general toxicology services — overlapping regulatory testing scope with Helix3 from a broader platform perspective.

Direct peers

• MB Research Labs: Independent preclinical CRO providing GLP genetic toxicology and general toxicology testing services to pharma, chemical, and medical device industries — comparable specialty CRO scale and customer base.
• Toxikon: Preclinical CRO providing GLP genotoxicity and safety assessment services for pharma, medical device, and biotech sponsors — overlapping GLP toxicology CRO profile.
• BSL Bioservice: GLP-contract laboratory offering a broad panel of genetic toxicology tests (Ames, micronucleus, comet, HPRT) for regulatory submissions, with a similarly focused European clientele.
• ITR Laboratories Canada: Preclinical CRO with a dedicated genetic toxicology / genotoxicity testing service line offering GLP in vivo and in vitro assays for regulatory submissions — directly comparable to Helix3's core offering.
• Gentronix: UK-based specialist genetic toxicology CRO focused on in vitro and in vivo genotoxicity assays under GLP, including comet assay expertise — overlapping niche positioning with Helix3.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/helix3-inc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helix3